84. Sarcoidosis Clinical trials / Disease details
Clinical trials : 149 / Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169
Showing 1 to 10 of 149 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05696795 (ClinicalTrials.gov) | May 1, 2023 | 13/1/2023 | Janus Kinase Inhibition in Sarcoidosis | JAK1 Inhibition in Sarcoidosis: an Opportunity for Pathogenesis Directed Therapy | Sarcoidosis | Drug: Abrocitinib 200 mg | Yale University | Pfizer | Not yet recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States |
| 2 | NCT05689879 (ClinicalTrials.gov) | February 7, 2023 | 2/5/2022 | Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis | Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis : a Prospective, Randomized, Controlled Trial Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis: a Prospective, Randomize ... | Sarcoidosis | Drug: STOP arm | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 90 | Phase 3 | NULL |
| 3 | NCT05499637 (ClinicalTrials.gov) | November 15, 2022 | 22/6/2022 | [68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation | Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinica ... | Acute Cellular Graft Rejection;Cardiac Sarcoidosis;Myocarditis Due to Drug | Drug: [68Ga]Ga-PentixaFor PET/CT | John O. Prior | NULL | Recruiting | 18 Years | N/A | All | 69 | Phase 2 | Switzerland |
| 4 | NCT05415137 (ClinicalTrials.gov) | September 15, 2022 | 8/6/2022 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ... | Pulmonary Sarcoidosis | Drug: Efzofitimod 3 mg/kg;Drug: Efzofitimod 5 mg/kg;Drug: Placebo | aTyr Pharma, Inc. | Kyorin Pharmaceutical Co.,Ltd | Recruiting | 18 Years | 75 Years | All | 264 | Phase 3 | United States;Japan;Netherlands;Puerto Rico;Spain |
| 5 | EUCTR2021-004794-31-NL (EUCTR) | 01/07/2022 | 10/05/2022 | A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory disease | A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis - Resolve-Lung A Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the ... | chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] chronic pulmonary sarcoidosis MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulm ... | Product Name: Namilumab Product Code: KIN-1902 INN or Proposed INN: NAMILUMAB | Kinevant Sciences GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | France;United States;Belgium;Turkey;Germany;Netherlands;United Kingdom | ||
| 6 | NCT05351554 (ClinicalTrials.gov) | June 30, 2022 | 4/4/2022 | A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Ca ... | A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac Sarcoidosis A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess t ... | Sarcoidosis, Cardiac | Drug: Namilumab;Drug: Placebo;Drug: Open label Namilumab | Kinevant Sciences GmbH | NULL | Terminated | 18 Years | N/A | All | 1 | Phase 2 | United States |
| 7 | NCT05314517 (ClinicalTrials.gov) | April 30, 2022 | 30/3/2022 | A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoi ... | A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary Sarcoidosis A Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the ... | Sarcoidosis, Pulmonary | Drug: Namilumab;Drug: Placebo | Kinevant Sciences GmbH | NULL | Recruiting | 18 Years | N/A | All | 100 | Phase 2 | United States;Belgium;France;Netherlands |
| 8 | NCT05247554 (ClinicalTrials.gov) | March 1, 2022 | 9/2/2022 | Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary Sarcoidosis Randomized Controlled Trial of Hydroxychloroquine Combined With Low-dose Corticosteroid in Pulmonary ... | Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticosteroid Therapy in Pulmonary Sarcoidosis Randomized Controlled Trial Testing the Effect of Hydroxychloroquine Combined With Low-dose Corticos ... | Pulmonary Sarcoidosis | Drug: Hydroxychloroquine + low-dose prednisone;Drug: Prednisone | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | 80 Years | All | 200 | Phase 3 | NULL |
| 9 | NCT04924270 (ClinicalTrials.gov) | January 2022 | 7/6/2021 | Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory Diseases Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diag ... | Safety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatment-naïve Patients With Newly Diagnosed Rheumatoid Arthritis, Reactive Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Gouty Arthritis, Psoriasis, Hidradenitis Suppurativa, Pulmonary Sarcoidosis, Crohn's Disease, and Ulcerative Colitis: a 52-week, Double-blind, Randomised, Placebo-controlled, Exploratory Trial Safety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatmen ... | Rheumatoid Arthritis;Reactive Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Gouty Arthritis;Psoriasis;Hidradenitis Suppurativa;Pulmonary Sarcoidosis;Crohn Disease;Ulcerative Colitis Rheumatoid Arthritis;Reactive Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Gouty Arthritis;P ... | Biological: Faecal microbiota transplantation;Other: Placebo | Torkell Ellingsen | Region of Southern Denmark;University of Southern Denmark | Not yet recruiting | 18 Years | 70 Years | All | 200 | Phase 2 | NULL |
| 10 | JPRN-jRCTs011210048 | 05/11/2021 | 05/11/2021 | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial - CHASM CS- RCT | Cardiac Sarcoidosis Cardiac Sarcoidosis | Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either: 1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or 2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6 months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for one month then STOP Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive either ... | Toshiyuki Nagai | NULL | Pending | >= 18age old | Not applicable | Both | 194 | Phase 3 | Canada;United States;United Kingdom;Japan |